Online-haemodiafiltration vs. conventional haemodialysis: a cross-over study by Guillaume Jean et al.
Jean et al. BMC Nephrology  (2015) 16:70 
DOI 10.1186/s12882-015-0062-0RESEARCH ARTICLE Open AccessOnline-haemodiafiltration vs. conventional
haemodialysis: a cross-over study
Guillaume Jean*, Jean-Marc Hurot, Patrik Deleaval, Brice Mayor and Christie LorriauxAbstract
Background: The main short-term advantages of haemodiafiltration (HDF) are supposedly better removal of Beta2-
microglobulin (ß2-m) and phosphate, and better haemodynamic stability. The main disadvantage is higher costs.
The aim of the study was to compare the clinical and biological parameters associated with HDF and high-flux
haemodialysis (HD), using a cross-over design, while maintaining the same dialysis parameters.
Methods: All patients on a 3 × 4 hours schedule were observed during 3 identical 6-months periods: HDF1 – HD –
HDF2. The mean values for the 2 last months of each period were compared.
Results: A total of 51 patients (76 % males, 45 % diabetic) with a mean age of 74 ± 15 years, and who had been on
dialysis for 49 ± 60 months were included. The mean blood flow (329 ± 27 ml/min), dialysate flow (500 ml/min), and
convection volumes (21.6 ± 3.2 L) were recorded. Patient medications were not changed. Predialysis blood pressure,
phosphataemia, calcaemia, iPTH, Kt/V, nPNA and intradialytic events were similar throughout the 3 periods. Only
serum albumin (34. 4 ± 3.6, 35.9 ± 3.4, 34.1 ± 4 g/L, p < 0. 0001) and ß2-m serum levels (26.1 ± 5.4, 28 ± 6, 26.5 ±
5 mg/L, p < 0.001, values shown for HDF1, HD, HDF2, respectively) were significantly lower during the HDF periods.
Factor associated with higher delta serum albumin levels between HD and HDF periods was mainly a lower
convection volume.
Conclusion: Comparing HDF and HD, we did not observe any differences in haemodynamic stability or in serum
phosphate levels. Only serum ß2-m (−6 % vs. HD) and albumin (−5 % vs. HD) levels changed. The long-term clinical
consequences of these biochemical differences should be prospectively assessed.
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PhosphataemiaBackground
In order to increase mid-to-large molecule clearance by
combining diffusive and convective transport, online
haemodiafiltration (HDF), using ultrapure dialysate, was
introduced [1]. In the past decade, evidence has accumu-
lated regarding the superiority of postdilution HDF over
haemodialysis (HD). Specifically, HDF has been associ-
ated with higher survival rates compared with low- [2]
and high-flux HD [3], when using high convection
volumes as prescribed in a recent prospective study re-
ported by Maduell et al. [4]. Additionally, HDF has been
reported to provide better hemodynamic stability [4, 5],
especially when using higher convective volumes [6]; a* Correspondence: guillaume-jean-crat@wanadoo.fr
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unless otherwise stated.better quality of life [7]; and fewer depression symptoms
[8]. HDF has also been reported to improve beta2-
microglobulin (ß2-m) [2, 9], phosphate [9, 10] and urea
removal [2, 9]. Some others studies have reported better
anaemia correction [11] and lower inflammation [12]
when using HDF. The main disadvantages of HDF are
its cost [13] and the loss of albumin [14, 15].
Previously at our institution, the conventional HD
protocol was 5 hours 3 times weekly using high-flux
HD. In December 2009, for organizational and cost rea-
sons, it was changed to 4 hours, and it has been hypoth-
esized that the efficiency of postdialysis online HDF
could compensate for the missed hour of therapy. The
aim of the present study was to compare postdilution
HDF and high-flux HD, in term of their clinical and
biological parameters, using a cross-over design.is is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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We took the opportunity of the dialysis centre being
relocated and the need for water treatment validation to
interrupt HDF during 6 months allowing a cross-over
follow-up.
In December 2010, all patients on a 3 × 4-hours sched-
ule were prospectively observed during 3 × 6-months
periods that included HDF1, HD and HDF2, after in-
formed consent was obtained. The study protocol was
ethical according to national standards of human experi-
mentation and the Declaration of Helsinki. Due to lack
of randomization, a local committee advice was not
mandatory.
The primary objective was to compare the effect of post-
dilution online HDF with high-flux HD on dialysis dose,
blood pressure control, intradialytic tolerance (symptom-
atic hypotension episodes and cramps), nutrition (dry
body weight, normalized protein catabolic rate, albumin),
anemia, and serum phosphate and ß2-m levels. The inclu-
sion criteria were patients aged ≥18 years with end-stage
renal disease (ESRD) receiving thrice-weekly HDF for ≥
3 months. Exclusion criteria included active systemic dis-
eases, liver cirrhosis, malignancies, single- needle dialysis,
and use of temporary non-tunnelized catheters.
Patients were dialyzed thrice-weekly, with a 4-hour
schedule, using a Fresenius 5008 console and polysul-
fone high-flux filter (FX80 and FX100, Fresenius S.E.,
Bad-Homburg, Germany). The composition of dialysate
and the HDF infusate was the same throughout the 3 pe-
riods: sodium 138–140 mmol/L, potassium 2–3.0 mmol/
L, calcium 1.25–1.75 mmol/L, magnesium 0.5 mmol/L,
chloride 106–109 mmol/L, bicarbonate 34–37 mmol/L,
acetate 3–4 mmol/L, and glucose 1.0 g/L. The dialysate
calcium concentration varied from 1.25 to 1.75 mmol/l,
according to the serum level of parathyroid hormone
(PTH), calcium, and bone markers serum levels as re-
ported previously [16]. Both HDF and HD were performed
with ultrapure dialysis fluids. In HDF, convection volume
was driven automatically using the “auto sub” system of
the 5008 machine.
The blood and dialysate flow rates, and dialysate compos-
ition, were kept constant during the 3 periods. Antihyper-
tensive medications and bone-mineral-related treatments
were maintained stably.
The following parameters were recorded at baseline and
at every session: dialyzer characteristics, dialysis time,
blood flow rate, dialysate flow rate, vascular access, dry
body weight, predialysis and postdialysis body weight,
convective volume, and pre- and postdialysis systolic and
diastolic blood pressures (BPs). The following laboratory
data were recorded at baseline and every month: predialy-
sis urea, creatinine, bicarbonate, sodium, brain natriuretic
peptide (BNP), potassium, calcium, phosphate, intact PTH
and haemoglobin. Other parameters that were recordedbimonthly included serum albumin, ß2-m and C-reactive
protein levels.
Hydratation status was assessed using a body composition
monitor (BCM, Fresenius Medical Care S.E., Bad-Homburg,
Germany) and the postdialysis value was recorded.
Using predialysis and postdialysis urea concentrations
in a mid-week dialysis session, the dialysis dose (Kt/V by
Daugirdas’ second-generation single-pool, variable vol-
ume formula) and normalized protein catabolic rate
(nPCR) were calculated by standard formulas. All la-
boratory determinations were performed locally (Grand
Vallon laboratory, NOVESCIA, Lyon, France). The doses
of erythropoiesis-stimulating agents, antihypertensive
drugs, vitamin D, cinacalcet and phosphate binders were
also recorded at baseline and every 3 months.
Statistical analysis
Statistical analyses were carried out using MedCalc© soft-
ware 11.5.1.0 (MedCalc Software, Mariakerke, Belgium).
The mean biological values for the last 2 months of each
period were retained for analysis. The mean values during
each period, for BP, convective volume, hypotension,
cramps and dry body weight, were recorded.
The differences between the 3 periods were investigated
using ANOVA and a paired t-test. The correlations be-
tween parameters were analyzed using a Pearson’s test,
when the distribution was normal, and by Spearman’s
rank test if there was a non-normal distribution. Logistic
regression was used when necessary. A Receiver operator
analysis (ROC) was generated when necessary. Through-
out the analysis, the p < 0.05 probability level was con-
sidered statistically significant. Data are presented as
mean ± SD.
Results
Among the 75 initial patients, 15 died, 6 underwent suc-
cessful kidney transplantation, and 3 were lost to follow-
up due to centre changes; the 51remaining patients were
the subjects of the present investigation. These patients
had a mean age of 74 ± 15 years, were predominantly male
(76 %), included a large number of diabetics (45 %), and
had been undergoing dialysis for 49 ± 60 months.
Dialysis filters were FX 80 or FX 100 polysulfone
(Fresenius© Bad Homburg Germany), native AV fistulas
were used in 86.5 % of patients, and the mean dialysate
calcium was 1.52 mmol/L. All these parameters were
stable throughout the study.
The comparison of the biological and treatment
parameters, during the 3 periods, is displayed in Table 1.
Throughout the study, the number of patients receiving
particular types of medications remained constant through-
out the 3 periods: alfacalcidol (35 %, 37 %, 37 % of pa-
tients), calcium-based phosphate binders (50 %, 48 %,
48 %), sevelamer (31 %, 31 %, 33 %), cinacalcet (5.8 %,
Table 1 Comparison of biological and treatment parameters between the 3 periods
HDF1 HD HDF2
Albumin (g/l) 34.4 ± 3 35.9 ± 3** 34.1 ± 4
ß2-microglobumin (mg/l) 26.1 ± 5 28 ± 6* 26.5 ± 5
Calcaemia (mmol/l) 2.2 ± 0.1 2.19 ± 0.1 2.18 ± 0.1
Phosphataemia (mmol/l) 1.58 ± 0.2 1.59 ± 0.3 1.61 ± 0.2
iPTH (pg/ml) 215 ± 110 220 ± 111 245 ± 108
Kt/V 1.67 ± 0,2 1.71 ± 0.25 1.74 ± 0.25
nPCR (g/kg/d) 1 ± 0.1 1.08 ± 0,19 1.05 ± 0,19
CRP mg/l 7.5 ± 9 7 ± 8 7.7 ± 8
Hb (g/dl) 11.7 ± 1 11.8 ± 0.8 11.7 ± 0.7
BNP (pg/ml) 445 ± 478 398 ± 466 408 ± 485
sBP/dBP (mmHg) 133/61 ± 17/11 132/59 ± 18/11 134/61 ± 18/11
Dry body weight [37] 72.6 ± 11 72 ± 12 72.1 ± 12
Interdialytic weight gain [37] 1.8 ± 0.6 2 ± 0.6 2 ± 0.7
BCM OH-post (Litre) −0.96 ± 1.4 −1.01 ± 1.5 −1.06 ± 1.5
Dialysate calcium (mmol/L) 1.51 ± 0.2 1.56 ± 0.2 1.54 ± 0.17
Blood flow rate (m/min) 330 ± 30 328 ± 27 329 ± 26
Dialysate Flow rate (mL/min) 500 500 500
Convection volume (Litre) 22.2 ± 3.3 0 21 ± 3.1
Hypotension/ cramps (% session) 15.7 12 20
Antihypertensive medications unit/day (%) 1.2 ± 0.4 (37.3) 1.2 ± 0.4 (37.3) 1.2 ± 0.4 (37.3)
ESA U/week 5000 ± 4000 4660 ± 3500 4900 ± 3500
Alfacalcidol μg/week (%) 2.2 ± 1 (37) 2.1 ± 1 (37) 2.1 ± 1 (35)
Calcium unit/d (%) 1.9 ± 2 (48) 1.88 ± 2.2 (50) 1.9 ± 2.2 (48)
Cinacalcet mg/d (%) 52 (5.8) 52 (5.8) 47 (7.8)
Sevelamer unit/d (%) 3.3 ± 4 (31) 3.4 ± 4 (33) 4 ± 4 (33)
*p < 0.001, **p < 0.0001 vs. other periods (ANOVA)
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periods) and native vitamin D (100 % in all 3 periods).
Predialysis systolic and diastolic BPs and the incidence of
intradialytic symptoms were not significantly different
during the 3 periods. Similarly, the dialysis dose remained
stable, with mean Kt/V ranging from 1.67 ± 0.2 to 1.74 ±
0.2 Haemoglobin, transferrin saturation index, and ferritin
did not differ. There were no differences in the proportion
of patients treated with distinct ESA (85 %). Intravenous
iron supplements (150 to 180 mg/months) and ESA doses
did not differ between the periods.
Only serum albumin concentrations (34. 4 ± 3.6, 36 ±
3.4, 34.1 ± 4 g/L, p < 0. 0001, Fig. 1) and ß2-m serum levels
(26.1 ± 5.4, 28 ± 6, 26.5 ± 5 mg/L, p < 0.001, Fig. 2) were
significantly different during the 3 periods (HDF1, HD,
HDF2). Compared with HD, 31/51 patients (60 %) had
lower serum albumin levels during HDF1 (Δ -1 to −10
g/L) and 26/51 patients (50.9 %) displayed lower albumin
levels during both HDF periods. Factors associated with
higher Δ serum albumin levels during the HD and HDFperiods included diabetes (64 % vs. 23 %, p = 0.04), lower
serum albumin in HDF1 (33.2 ± 3.9 vs. 35.7 ± 3 g/L, p =
0.01) and lower convection volumes (20.8 ± 2.5 vs. 22.9 ±
2.4 L, p = 0.04). Convection volume was similar in diabetic
and non-diabetic patients (21.3 ± 3.8 vs. 21.9 ± 2.8 L). The
serum albumin level in HDF1 was similar in diabetic and
non-diabetic patients (33 ± 2.8 vs. 34.4 ± 3.7 g/L).
Delta albumin demonstrated inverse relationship with
convective volume (Fig. 3) and albumin in HDF1 period
(Fig. 4). However, using logistic regression, only low con-
vective volume remained associated with higher delta al-
bumin (Table 2). The best cut-off value was 21 L, with a
specificity of 76.9 % and a sensitivity of 64 % (Area under
the curve = 0.75 [0.607 to 0.859], p = 0.004).
Also during the study, 31/51 (60.7 %) patients had
lower serum ß2-m values during HDF1 than during HD,
and 32/51 (62.7 %) had lower ß2-m values in HDF2 than
during the HD period (Fig. 2). The only factor associated
with the absence of ß2-m decline during the HDF pe-
riods was diabetes (72 % vs. 28 %, p = 0.01).
Fig. 1 Comparison of serum albumin value between the 3 periods (Paired t-test): Alb HDF1 (34.4 ± 3 g/L) vs. Alb HD (35.9 ± 3 g/L), mean
difference 1.5 ± 2.5 g/L, p = 0.0001; Alb HD vs. Alb HDF2 (34.1 ± 3.9 g/L) mean difference 1.8 ± 2.6 g/L, p < 0.0001; Alb HDF1 vs. HDF2, mean
difference 0.3 ± 3 g/L, p = 0.43
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In this cross-over study comparing 3 consecutive of
6-month periods (HDF1 −HD −HDF2), we found that
HDF protocols were associated with lower albumin and
ß2-m serum levels. No others clinical or biological
parameters were found to differ during the 3 periods. A
convective volume < 21 L was associated with the lower
albumin levels during HDF.Fig. 2 Comparison of serum ß2-m values between the 3 periods (Paired t-
difference 1.9 ± 3.6, p = 0.0003; ß2-m HD vs. ß2-m HDF2 (26.5 ± 4.9 mg/L) m
difference 0.3 ± 2.7 mg/L, p = 0.37In a 4-years observational study in 2006, slight de-
creases in serum albumin and prealbumin levels were re-
ported during the first 6 months following a switch from
HD to HDF with increased levels observed thereafter
[17]. Ok et al. also reported lower albumin levels in the
low-efficiency HDF arm of their prospective Turkish
study [3]. Decreased serum albumin levels during the
first 6 months have also been reported after switchingtest): ß2-m HDF1 (26.1 ± 5 mg/L) vs. ß2-m HD (28 ± 6 mg/L), mean
ean difference 1.5 ± 3, p = 0.0009; ß2-m HDF1 vs. HDF2, mean
Fig. 3 Linear regression between convective volume in HDF1 and delta albumin between HD and HDF1 periods
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vations were not confirmed in a study in Balkan coun-
tries [19], and Movilli et al. reported the absence of an
albumin level decrease during an HDF protocol [9].
The lower serum albumin level observed during the
HDF periods in the present study could be due to a
dialysate albumin loss, as reported previously by Com-
barnous et al., who observed an albumin loss of 1000–
6800 mg/session [15]. In 2004, Ahrenholz et al. reported
a total albumin loss of 300–7000 mg/session, depending
on the type of dialyzer used [14]. Unfortunately, we did
not measure the albumin loss in the dialysate. In theFig. 4 Linear regression between serum albumin in HDF1 and delta albumCONTRAST study, de Hoedt et al. reported no differ-
ence in the rate of change in albumin between the HDF
and low-flux HD arms [20]. However, only annual data
was reported, and short-term evolution could have been
missed. As serum albumin decreased mainly in patients
with lower convection volume, the relationship between
the change in albumin levels and the HDF technique
itself remains unclear.
A decrease in ß2-m serum values during HDF was re-
ported by Zehnder et al., who demonstrated its absorp-
tion to the polysulfone membrane [10]. Others studies
have also reported a significant decrease in ß2-m levelsin between HD and HDF1 periods
Table 2 Logistic regression of factors associated with positive delta serum albumin between HDF1 and HD period
Variable Coefficient Std. error P Odds ratio 95 % CI
Convective volume L −0.25135 0.11949 0.0354 0.7777 0.6154 to 0.9830
Albumin g/L (HDF1) −0.20410 0.10276 0.0470 0.8154 0.6666 to 0.9973
Diabetes 0.16828 0.58480 0.7735 1.1833 0.3761 to 3.7229
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However, in the Turkish study, there were not differ-
ences between the 3 arms involving HDF and low- and
high-flux HD [3]. In the CONTRAST study, ß2-m de-
creased significantly in the HDF arm, especially in cases
when residual kidney function was low [2]. Lastly, in the
ESHOL study, ß2-m levels were similar between the HD
and HDF arm [4]. A role for residual renal function has
been hypothesized to account for this non-expected
evolution. However, the factors associated with ß2-m de-
cline during HDF have not been clearly reported. Our
observation that diabetes was associated with smaller
serum ß2-m decline requires further confirmation and
explanation.
The impact of serum ß2-m on the survival in haemo-
dialysis patients is controversial [23, 24] and depends on
the patient’s nutritional factors and diabetic status; how-
ever, the negative association of low albumin levels with
poor outcomes is clear [25]. Thus, a negative impact of
HDF on serum albumin would be expected to associate
with poor outcomes, but this effect has not been re-
ported in the literature. Even if the question of a survival
advantage for HDF is still under debate, the data do not
confirm any disadvantage for HDF compared with HD.
HDF was not observed to have any impact on mean
phosphate level or on phosphate binder requirements in
our study. The literature on this subject remains contro-
versial. In 1999, Zenhder et al. reported an increase in
phosphate clearance during HDF vs. high-flux HD [10].
In 2010, another group reported lower serum phosphate
levels in HDF-treated patients, but data on protein intake
or phosphate binders were not provided [26]. Lornoy et al.
reported higher phosphate removal during HDF when
compared with HD, especially in the low-normal phos-
phate range, but not in cases where phosphate levels were
high [27]. Others studies have also reported decreased
phosphate levels during HDF vs. HD [9, 28–30], mostly
using higher blood flow rates. However, in 1991, Man
et al. reported no advantage of HDF for phosphate mass
transfer [23], and Ok et al. reported no differences in
phosphate levels between HD and HDF groups [3]. Our
observation confirms that the impact of HDF on phos-
phate levels is not significant. Moreover, we did not
observed any changes in serum levels of PTH or bone
markers, unlike a previous study that demonstrated, re-
ductions in both PTH and bone alkaline phosphatase after
switching from HD to HDF [31]. However, calcium masstransfer, a potentially key point, was not evaluated as in
our study. Regarding small molecule clearance, we did not
find differences between periods similar to Zehnder et al.
who reported no advantage of HDF for urea and creatin-
ine clearance [10]. By contrast, Movilli et al. [9] and the
CONTRAST study [2] reported an increase in dialysis
dose when using HDF vs. low-flux HD, but higher blood
flow rates in the HDF arm may have biased the results.
We could not confirm any hemodynamic advantage of
HDF, as we did not observe any difference in the num-
ber of hypotensive episodes or changes in blood pressure
values during the 3 phases of the study. These finding
are not consistent with results from postdilution HDF
[5] and predilution HDF [32] studies. Additionally, the
ESHOL study reported fewer hypotensive episodes in
the HDF arm [4], especially when higher convective
volumes were achieved, as reported by Mora-Bravo et al.
[6]. However, the absence of a haemodynamic advantage
for HDF has also been reported under strictly controlled
conditions in 12 stable patients [33]. Similarly, no differ-
ence in blood pressure was found for HDF in association
with intracellular or extracellular volume changes during
sessions [34]. The favourable impact of HDF on haemo-
dynamic stability is hypothesized to be due to higher so-
dium mass transfer in some cases, even if this phenomenon
has been poorly documented.
We could not confirm better control of anaemia dur-
ing HDF, as reported by Vilar et al. in a large observa-
tional study [35], or the correction of anaemia with
reduced dose of ASE observed 9 months after switching
32 patients to HDF [11]. We also did not find any
significant changes in CRP levels during the 3 periods in
contrast to the results from a large multicenter crossover
study [36] and 2 observational studies [5, 12].
Our study has numerous limitations including that the
initial dialysis technique was not randomized, the size of
the studied cohort was small, and we did not measure
albumin loss in the dialysate. However, the cross-over
design of the study could give a more sound comparison
of the 2 modalities. Nevertheless, there was also some
drop out and the patients’ state may have changed after
6 or 12 months.
Conclusion
Comparing online postdilution HDF and high-flux HD
in a cross-over study, we observed no differences in pa-
tient haemodynamic stability, anaemia, inflammation or
Jean et al. BMC Nephrology  (2015) 16:70 Page 7 of 8serum phosphate levels. Only serum ß2-m (−6 % vs.
HD) and albumin (−5 % vs. HD) levels were significantly
different. The long-term clinical impact of these bio-
chemical observations, and their association with the
convective volume should be prospectively assessed.
Abbreviation
ß2-m: Beta2-microglobulin; BCM: Body composition monitor; BNP: Brain
natriuretic peptide; BP: Blood pressure; CRP: C-reactive protein; ESRD: End
stage renal disease; ESA: Erythropoiesis stimulating agent; HD: Haemodialysis;
HDF: Haemodiafiltration; nPCR: Normalized protein catabolic rate;
PTH: Parathyroid hormone.
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